BEAM Quote, Financials, Valuation and Earnings

Intellia Therapeutics, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -416.15%. Beam Therapeutics, Inc.'s return on equity of -7.83% beat Intellia Therapeutics, Inc.'s return on equity of -54.49%.

Beam Therapeutics, Inc. has a consensus price target of $51.20, signalling upside risk potential of 107.62%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $25.29 which suggests that it could grow by 92.58%. Given that Beam Therapeutics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Intellia Therapeutics, Inc..

Beam Therapeutics, Inc. has a beta of 2.185, which suggesting that the stock is 118.54% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 1.989, suggesting its more volatile than the S&P 500 by 98.932%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Beam Therapeutics, Inc. quarterly revenues are $114.1M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $23M. Beam Therapeutics, Inc.'s net income of $244.3M is higher than Intellia Therapeutics, Inc.'s net income of -$95.8M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 17.85x versus 20.78x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -90.43%. Beam Therapeutics, Inc.'s return on equity of -7.83% beat Pacific Biosciences of California, Inc.'s return on equity of -389.62%.

Beam Therapeutics, Inc. has a consensus price target of $51.20, signalling upside risk potential of 107.62%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.58 which suggests that it could grow by 92.79%. Given that Beam Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Beam Therapeutics, Inc. has a beta of 2.185, which suggesting that the stock is 118.54% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.332, suggesting its more volatile than the S&P 500 by 133.164%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Beam Therapeutics, Inc. quarterly revenues are $114.1M, which are larger than Pacific Biosciences of California, Inc. quarterly revenues of $44.6M. Beam Therapeutics, Inc.'s net income of $244.3M is higher than Pacific Biosciences of California, Inc.'s net income of -$40.4M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 17.85x versus 2.51x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tempus AI, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -14.75%. Beam Therapeutics, Inc.'s return on equity of -7.83% beat Tempus AI, Inc.'s return on equity of -72.44%.

Beam Therapeutics, Inc. has a consensus price target of $51.20, signalling upside risk potential of 107.62%. On the other hand Tempus AI, Inc. has an analysts' consensus of $75.43 which suggests that it could grow by 59.17%. Given that Beam Therapeutics, Inc. has higher upside potential than Tempus AI, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Tempus AI, Inc..

Beam Therapeutics, Inc. has a beta of 2.185, which suggesting that the stock is 118.54% more volatile than S&P 500. In comparison Tempus AI, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tempus AI, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Tempus AI, Inc. pays out 0.8% of its earnings as a dividend. Tempus AI, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Beam Therapeutics, Inc. quarterly revenues are $114.1M, which are smaller than Tempus AI, Inc. quarterly revenues of $367.2M. Beam Therapeutics, Inc.'s net income of $244.3M is higher than Tempus AI, Inc.'s net income of -$54.2M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Tempus AI, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 17.85x versus 6.54x for Tempus AI, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -29.42%. Beam Therapeutics, Inc.'s return on equity of -7.83% beat Twist Bioscience Corp.'s return on equity of -16.63%.

Beam Therapeutics, Inc. has a consensus price target of $51.20, signalling upside risk potential of 107.62%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $50.44 which suggests that it could grow by 0.47%. Given that Beam Therapeutics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Beam Therapeutics, Inc. is more attractive than Twist Bioscience Corp..

Beam Therapeutics, Inc. has a beta of 2.185, which suggesting that the stock is 118.54% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.206, suggesting its more volatile than the S&P 500 by 120.556%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Beam Therapeutics, Inc. quarterly revenues are $114.1M, which are larger than Twist Bioscience Corp. quarterly revenues of $103.7M. Beam Therapeutics, Inc.'s net income of $244.3M is higher than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 17.85x versus 7.88x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.